Elevation Oncology, Inc. announced plans to prioritize key research and development efforts to advance EO-3021, its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin18.2, and other pipeline programs including those through its existing partnership with Caris Life Sciences. Elevation Oncology is pausing further investment in the clinical development of seribantumab and realigning its resources to focus on advancing EO-3021 and other pipeline programs. Elevation Oncology intends to pursue further development of seribantumab only in collaboration with a partner.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.53 USD | -4.08% | -12.19% | +557.36% |
05-31 | Piper Sandler Starts Elevation Oncology With Overweight Rating, $10 Price Target | MT |
05-14 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+557.36% | 193M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ELEV Stock
- News Elevation Oncology, Inc.
- Elevation Oncology, Inc. Announces Plans to Prioritize Key Research and Development Efforts to Advance EO-3021